In 2017 HEMA had $20M in revenue. In 2015 they estimated the market for their products and services to be $500M with an expected tripling of that market by 2025. During 2018 they will be increasing the number of employees, moving to a much larger facility, moving into new markets and purchasing new equipment to prepare for the continuing and increasing demand for their products and services. In 2018 growth is expected to less than the previous 3 years due to the aforementioned capital expenditures. However, this is clearly an undiscovered gem in the biotech industry. With only 12M shares outstanding the stock could readily skyrocket over the next few years. A move to NASDAQ will hopefully occur in the not too distant future, however, they have mentioned nothing in that regard as of today.
